Sugi Predict

Sugi Predict / Compounds / SCHEMBL8453

SCHEMBL8453

SCHEMBL8453

OB(O)c1ccc(OCc2ccccc2)c(Cl)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ENPP2 Q13822 2/20 0.66
▸ NPC1 O15118 4/20 0.56
▸ RAB9A P51151 4/20 0.56
▸ SMN1; SMN2 Q16637 4/20 0.56
▸ NFKB1 P19838 2/20 0.56
▸ NFKB2 Q00653 2/20 0.56
▸ RELA Q04206 2/20 0.56
▸ LIPE Q05469 1/20 0.53
▸ MRGPRX4 Q96LA9 8/20 0.49
▸ HPGD P15428 4/20 0.47
▸ TP53 P04637 2/20 0.47
▸ XBP1 P17861 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ MITF O75030 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ RXRA P19793 1/20 0.47
▸ RXRB P28702 1/20 0.47
▸ ACP1 P24666 1/20 0.46
▸ PTPN12 Q05209 1/20 0.46
▸ PTPN13 Q12923 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29952431 1.00 ENPP2 (0.66) ENPP2NPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL9946040 0.88 ENPP2 (0.56) ENPP2NPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL544428 0.88 LIPE (0.53) ENPP2NPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL257576 0.87 ENPP2 (0.62) ENPP2NPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL16320521 0.85 LIPE (0.57) ENPP2NPC1RAB9ASMN1; SMN2LIPE
SCHEMBL12260343 0.85 ENPP2 (0.63) ENPP2NPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL10269960 0.85 ENPP2 (0.52) ENPP2NPC1RAB9ASMN1; SMN2NFKB1
SCHEMBL12261269 0.84 ENPP2 (0.62) ENPP2NPC1RAB9ASMN1; SMN2MRGPRX4
SCHEMBL257843 0.84 ENPP2 (0.59) ENPP2NPC1RAB9ASMN1; SMN2MRGPRX4
SCHEMBL15330173 0.83 ENPP2 (0.57) ENPP2NPC1RAB9ASMN1; SMN2NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8361484-B2 Polymer systems for lung volume reduction therapy AERIS THERAPEUTICS, INC. (US) 2013-01-29 — — US claimed
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy CANADIAN IMPERIAL BANK OF COMMERCE (CA) 2010-02-18 — — US claimed
EP-2059227-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY Aeris Therapeutics, Inc. (US) 2009-05-20 — — EP claimed
WO-2008039827-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY AERIS THERAPEUTICS, INC. (US) 2008-04-03 — — WO claimed
US-20260000781-A1 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF CIDARA THERAPEUTICS INC (US) 2026-01-01 — — US disclosed
EP-4551563-A2 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF CIDARA THERAPEUTICS, INC. (US) 2025-05-14 — — EP disclosed
WO-2025064869-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER CIDARA THERAPEUTICS, INC. (US) 2025-03-27 — — WO disclosed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
WO-2024010810-A2 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF CIDARA THERAPEUTICS, INC. (US) 2024-01-11 — — WO disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
EP-3414234-B1 BRUTON'S TYROSINE KINASE INHIBITORS ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO LTD (CN) 2022-06-29 — — EP disclosed
CN-108368107-B Fused heterocyclic compounds as S1P modulators 艾伯维公司 2021-11-26 — — CN disclosed
EP-1866293-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB Pharma, S.A. (BE) 2007-12-19 — — EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 — — WO disclosed
US-20070282101-A1 Indazole compounds ABBVIE INC. 2007-12-06 — — US disclosed
WO-2007068905-A1 1,2,4-TRIAZOL-l-YL BISPHENYL DERIVATIVES FOR USE IN THE TREATMENT OF ENDOCRINE-DEPENDENT TUMOURS STERIX LIMITED (GB) 2007-06-21 — — WO disclosed
WO-2007039146-A1 4-CARBOXY PYRAZOLE DERIVATIVES AS ANTI-VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2007-04-12 — — WO disclosed
US-20060223852-A1 Pyrazoles GILLESPIE PAUL 2006-10-05 — — US disclosed
WO-2006103045-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB PHARMA S.A. (BE) 2006-10-05 — — WO disclosed
WO-2005014525-A2 BI-ARYL COMPOUND HAVING IMMUNOSUPPRESSIVE ACTIVITY MITSUBISHI PHARMA CORPORATION (JP) 2005-02-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ENPP2 739/4885NPC1 1419/4885RAB9A 1297/4885
US-20070282101-A1 Indazole compounds CYP3A43, CYP3A7, UGT1A1 ENPP2 3575/4885NPC1 58/4885RAB9A 740/4885
US-20060223852-A1 Pyrazoles GPR119, PDK2, PC ENPP2 2749/4885NPC1 889/4885RAB9A 1873/4885
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy GFER, MUC1, CTH ENPP2 854/4885NPC1 4840/4885RAB9A 4705/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A ENPP2 463/4885NPC1 2061/4885RAB9A 1518/4885
US-20260000781-A1 FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF FCGR2A, FCGR1A, FCGR3B ENPP2 84/4885NPC1 1587/4885RAB9A 2879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.